Vivolux core competence is screening of potential new anticancer drug candidates and to develop candidate drugs on to early clinical trials by:

• Having access to fresh human cancer cells
• A sophisticated high-speed screening system (DAPS - Drug Activity Profiling System) for prediction of clinical success/failure in cancer treatment
• Using normal epithelial cells for counter-screening
• A unique 3-D method for study of apoptosis in spheres of human cancer cells
• Expertise in mechanism of action studies
• Extensive experience in using biomarkers for evaluating response to anticancer drugs
• Vast experience of drug development
• In depth knowledge of regulatory requirements
• Expertise in clinical trial methodology